(Q38171356)

30 August 2017

title

Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise (English)

1 reference

30 August 2017

Ramez N Eskander

1

1 reference

30 August 2017

James Cripe

series ordinal

2

1 reference

30 August 2017

Robert E Bristow

series ordinal

3

1 reference

30 August 2017

publication date

1 March 2014

1 reference

Current Treatment Options in Oncology

30 August 2017

published in

1 reference

30 August 2017

volume

15

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

27-40

1 reference

https://scigraph.springernature.com/pub.10.1007/s11864-013-0264-2

30 August 2017

exact match

0 references

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

21 January 2018

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Trials with impact on clinical management: first line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy in the treatment of advanced epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Hyperthermia in cancer growth regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

High volume intraperitoneal chemotherapy ("belly bath") for ovarian cancer. Pharmacologic basis and early results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Intraperitoneal chromic phosphate in ovarian cancer: risks and benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: interim analysis of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Low surface contamination by cis/oxaliplatin during hyperthermic intraperitoneal chemotherapy (HIPEC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Selection criteria for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Survival and quality of life following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colonic origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Evaluation of Extensive Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Epithelial Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

Re: “Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase II trial.” — Proposal of a clinical trial of cytoreductive surgery and hyperthermic in

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0264-2

A clinical investigation of total-body hyperthermia as cancer therapy

21 January 2018

1 reference

12 December 2020

The effect of early enteral nutrition on hyperthermic intraoperative intraperitoneal chemotherapy-induced mucosal permeability following gastrectomy

1 reference

12 December 2020

Efficacy of intraperitoneal continuous hyperthermic chemotherapy as consolidation therapy in patients with advanced epithelial ovarian cancer: a long-term follow-up.

1 reference

12 December 2020

Role of whole-body hyperthermia in the treatment of neoplastic disease: its current status and future prospects.

1 reference

12 December 2020

Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis

1 reference

12 December 2020

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients

1 reference

12 December 2020

Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan

1 reference

12 December 2020

A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer

1 reference

12 December 2020

Intraperitoneal hyperthermic chemotherapy in ovarian cancer

1 reference

12 December 2020

1 reference

12 December 2020

Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells

1 reference

12 December 2020

Use of nitrogen mustard in treatment of serous effusions of neoplastic origin

1 reference

12 December 2020

Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer

1 reference

12 December 2020

Intraperitoneal chemotherapy and the NCI clinical announcement

1 reference

12 December 2020

Intraperitoneal administration of Taxol in the management of ovarian cancer

1 reference

12 December 2020

Clinical delivery system for intraperitoneal hyperthermic chemotherapy.

1 reference

12 December 2020

Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients

1 reference

12 December 2020

Patient rated outcomes and survivorship following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS + HIPEC).

1 reference

12 December 2020

Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer -- 12-year single center experience

1 reference

12 December 2020

Possible benefits of hyperthermia to chemotherapy

1 reference

12 December 2020

Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer

1 reference

12 December 2020

Complete parietal and visceral peritonectomy of the pelvis for advanced primary and recurrent ovarian cancer

1 reference

12 December 2020

Radiation and hyperthermia

1 reference

12 December 2020

Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study

1 reference

12 December 2020

Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer: A critical need for an evidence-based evaluation

1 reference

12 December 2020

Whole body hyperthermia and intraperitoneal carboplatin in residual ovarian cancer

1 reference

12 December 2020

Intraperitoneal hyperthermic treatment of implanted peritoneal cancer in rats

1 reference

12 December 2020

Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma

1 reference

12 December 2020

Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer

1 reference

12 December 2020

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

1 reference

12 December 2020

10.1007/S11864-013-0264-2

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1006145839

0 references

1 reference